Deucravacitinib Shows Durable Efficacy in Psoriasis Over 2 Years, finds study

Real world data are limited on two year effectiveness of tyrosine kinase 2 inhibitor deucravacitinib for psoriasis, especially data stratified by body mass index or age. This study aimed to evaluate one hundred four week effectiveness of deucravacitinib in patients with psoriasis, stratified by body mass index (less than twenty five versus greater than or equal to twenty five kilograms per square meter) or age (less than sixty five versus greater than or equal to sixty five years). They included one hundred twenty-seven patients with moderate to severe psoriasis who received deucravacitinib six milligrams once daily. Psoriasis area and severity index decreased throughout one hundred four weeks in all patients. In between group comparisons, mean percent reduction of psoriasis area and severity index did not significantly differ at any time point in either body mass index or age stratification. The amount of decreasing psoriasis area and severity index and achievement rates of seventy five percent improvement, ninety percent improvement, and absolute psoriasis area and severity index less than or equal to two through week sixteen to sixty eight were slightly higher in patients with body mass index less than twenty five than in those with body mass index greater than or equal to twenty five, after which the order was inverted. The achievement rates of complete clearance or absolute psoriasis area and severity index less than or equal to one were higher in patients with body mass index less than twenty five throughout one hundred four weeks. At week one hundred four, complete clearance or absolute psoriasis area and severity index less than or equal to one rates were sixteen point seven percent or fifty four point two percent in the body mass index less than twenty five group, while zero percent or forty percent in the body mass index greater than or equal to twenty five group, respectively. Percent reduction of psoriasis area and severity index and achievement rates of seventy five percent and ninety percent improvement were slightly higher in patients aged greater than or equal to sixty five years than in those aged less than sixty five years by week fifty two, after which the order was inverted. At week one hundred four, achievement rates of complete clearance or absolute psoriasis area and severity index less than or equal to one were twenty eight point six percent or fifty seven point one percent in patients aged less than sixty five years, while zero percent or forty six point seven percent in patients aged greater than or equal to sixty five years, respectively.

Deucravacitinib reduced psoriasis area and severity index throughout one hundred four weeks in all patients. Patients with body mass index less than twenty five or age greater than or equal to sixty five years might show slightly higher response to deucravacitinib at early time points around one year, whereas patients with body mass index greater than or equal to twenty five or age less than sixty five years might show slightly higher response at later time points. Patients with body mass index greater than or equal to twenty five or age greater than or equal to sixty five years might have difficulty maintaining complete clearance through week one hundred four.

Reference:

Y. Okabe, T. Hagino, Y. Takahashi, H. Saeki, E. Fujimoto, and N. Kanda, “ Two-Year Real-World Effectiveness of Deucravacitinib 6 mg in Psoriasis: A Single-Center Analysis Stratified by Body Mass Index or Age in a Japanese Cohort,” The Journal of Dermatology (2026): 1–10, https://doi.org/10.1111/1346-8138.70137.

Keywords:

Y. Okabe, T. Hagino, Y. Takahashi, H. Saeki, E. Fujimoto, and N. Kanda, deucravacitinib, psoriasis, tyrosine kinase 2 inhibitor, long-term effectiveness, real-world study, body mass index, age stratification, psoriasis area and severity index, treatment response, dermatology